Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Boehringer Ingelheim
Johnson and Johnson
Dow

Last Updated: April 1, 2023

Investigational Drug Information for Buparlisib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions


What is the drug development status for Buparlisib?

Buparlisib is an investigational drug.

There have been 40 clinical trials for Buparlisib. The most recent clinical trial was a Phase 3 trial, which was initiated on October 3rd 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

Recent Clinical Trials for Buparlisib
TitleSponsorPhase
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCCAdlai Nortye Biopharma Co., Ltd.Phase 3
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaJanssen Scientific Affairs, LLCPhase 1
A Clinical Trial of Buparlisib and Ibrutinib in LymphomaNovartis PharmaceuticalsPhase 1

See all Buparlisib clinical trials

Clinical Trial Summary for Buparlisib

Top disease conditions for Buparlisib
Top clinical trial sponsors for Buparlisib

See all Buparlisib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Merck
Boehringer Ingelheim
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.